Who is sponsoring NCT06247709?

NCT06247709 is sponsored by Federico II University.

What drugs are being tested in NCT06247709?

Interventions in NCT06247709: Immunohistochemical expression in pitNET cells of KLHL14.

What condition does NCT06247709 study?

NCT06247709 studies Invasiveness, Neoplasm.

Is NCT06247709 still recruiting?

NCT06247709 is currently completed. Last updated 8 February 2024.

Last reviewed 2024-02-08 · How we verify

NCT06247709

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KLHL14 Expression as Predicting Factor of Invasiveness in pitNET

Completed Last updated 8 February 2024

What this trial tests

trial testing Immunohistochemical expression in pitNET cells of KLHL14 in Invasiveness, Neoplasm in 12 participants. Completed in 17 December 2023.

Timeline

12 March 2023

Primary endpoint
31 October 2023

17 December 2023

Quick facts

Lead sponsor	Federico II University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	12 March 2023
Primary completion	31 October 2023
Estimated completion	17 December 2023
Sites	1 location across Italy

Drugs / interventions tested

Immunohistochemical expression in pitNET cells of KLHL14

Conditions studied

Invasiveness, Neoplasm — all drugs for Invasiveness, Neoplasm →

Sponsor

Federico II University

Who can join

Adults 18 to 70, any sex, with Invasiveness, Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

OBJECTIVE: The objective of this study is to evaluate the correlation between KLHL14 expression and its cytoplasm-nuclear localisation and pituitary adenomas biological behaviour with particular focus on its role in epithelial mesenchymal transition and invasion of para and suprasellar regions. This is a multicenter and multidisciplinary study, with the involvement of the Departments of Neurosurgery of the University of Naples Federico II and the Department of Biosciences of the University of Teramo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

KLHL14 and E-Cadherin Nuclear Co-Expression as Predicting Factor of Nonfunctioning PitNET Invasiveness: Preliminary Study.
Berardinelli J, Russo V, Canciello A, Di Giacinto O, et al · · 2024 · cited 2× · PMID 39124679 · DOI 10.3390/jcm13154409

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06247709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 8 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06247709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing